Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
4.13
0.02 (0.49%)
At close: Aug 15, 2025, 3:59 PM
4.06
-1.57%
After-hours: Aug 15, 2025, 05:58 PM EDT
Aquestive Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -13.55M | -22.93M | -17.05M | -11.51M | -2.75M | -12.83M | -8.11M | -2.04M | -5.79M | 8.07M | -12.35M | -12.54M | -16.3M | -13.22M | -28.95M | -14.55M | -12.37M | -14.67M |
Depreciation & Amortization | 140K | 139K | 147K | 159K | 205K | 207K | 467K | 263K | 289K | 325K | 397K | 596K | 667K | 727K | 731K | 736K | 742K | 755K |
Stock-Based Compensation | 1.88M | 1.59M | 2.4M | 1.58M | 1.54M | 1.58M | 940K | 774K | 631K | 344K | 714K | 535K | 2.22M | 913K | 1.69M | 1.9M | 1.72M | 1.51M |
Other Working Capital | 3.52M | -2.61M | -651K | -4.17M | -8.45M | -2.51M | -446K | -1.74M | -692K | 1.21M | 24.34M | 3.31M | 4.62M | -4.27M | -196K | 1.09M | 1.86M | 810K |
Other Non-Cash Items | 2.69M | 2.8M | 2.73M | 2.73M | 2.36M | 2.71M | 5.39M | 88K | 52K | -204K | -54K | 2.23M | 1.89M | 1.78M | 1.87M | 4.82M | 4.34M | 4.65M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -2.53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 13.82M | n/a | n/a | n/a |
Change in Working Capital | 919K | -4.99M | 5.28M | -4.83M | -8.36M | -2.05M | -1.1M | -1.44M | -3.09M | 283K | 19.74M | 11.98M | 4.96M | -4.68M | 2.77M | -1.97M | 3.81M | -6.34M |
Operating Cash Flow | -7.91M | -23.4M | -6.49M | -11.88M | -7.01M | -10.38M | -4.94M | -2.35M | -7.91M | 8.82M | 8.45M | 2.81M | -6.56M | -14.48M | -8.06M | -9.06M | -1.76M | -14.1M |
Capital Expenditures | -107K | -135K | -15K | -80K | -35K | -29K | -16K | -151K | -826K | -2K | -26K | -1.72M | -677K | -104K | -533K | -83K | -194K | -103K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2.52M | -1.5M | n/a | n/a | -533K | n/a | n/a | n/a |
Investing Cash Flow | -107K | -135K | -15K | -80K | -35K | -29K | -16K | -151K | -826K | -2K | -26K | -1.72M | -677K | -104K | -533K | -83K | -194K | -103K |
Debt Repayment | -8K | -11K | -5K | -8K | -5K | -5K | -38.98M | 1.02M | -3.46M | -9.09M | -675K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 32K | -703K | 84.15M | -202K | 25K | -354K | 39.26M | 3.77M | 3.57M | -1.03M | -5.86M | -682K | 5.22M | n/a | 266K | -9K | 72K | n/a |
Financial Cash Flow | -100K | 20.65M | 157K | -17K | 1.71M | 81.74M | 3.91M | 4.98M | 4.29M | -9.21M | 204K | -138K | 10.2M | 1.3M | 5.45M | 6.08M | 8.69M | 9.89M |
Net Cash Flow | -8.12M | -2.89M | -6.35M | -11.98M | -5.33M | 71.33M | -1.04M | 2.48M | -4.45M | -391K | 8.62M | 954K | 2.96M | -13.29M | -3.14M | -3.07M | 6.74M | -4.31M |
Free Cash Flow | -8.02M | -23.54M | -6.5M | -11.96M | -7.04M | -10.41M | -4.96M | -2.5M | -8.73M | 8.81M | 8.42M | 1.09M | -7.24M | -14.59M | -8.59M | -9.15M | -1.95M | -14.2M |